Digital therapeutic maker Happify Well being is partnering with neuroscience-focused pharma firm Biogen on a digital engagement and training platform for a number of sclerosis.
The product will embrace Happify’s group for folks dwelling with MS, in addition to entry to neurology suppliers like docs and nurses, psychological well being professionals, dietitians and rehabilitation professionals. Biogen will contribute instructional content material and affected person care sources.
“This collaboration is one in every of some ways we’re centered on supporting sufferers by assembly them the place they’re. The mixture of Biogen’s experience in neuroscience and our dedication to digital well being, together with Happify Well being’s AI and digital therapeutic capabilities, will assist drive a linked and complete expertise that permits sufferers to really feel supported all through their journey,” Jason Hawbecker, head of strategic partnerships and collaborations at Biogen, mentioned in an announcement.
“We’re excited in regards to the potential of this partnership to supply general help for the MS group.”
WHY IT MATTERS
In keeping with the National Multiple Sclerosis Society, almost a million folks have MS within the U.S. The illness could cause symptoms like numbness or tingling, weak spot, issue strolling, imaginative and prescient issues and dizziness.
Happify is pitching the collaboration as a method to enhance a affected person’s care journey and maintain them knowledgeable about their situation.
“It may be difficult for folks dwelling with MS to remain up-to-date with the newest remedies, interpret new signs or examine modifications of their well being that will or will not be associated to MS,” Ofer Leidner, president of Happify Well being, mentioned in an announcement.
“We’re offering the MS group with an answer configured to accommodate their particular wants, in addition to alternatives to interact with specialists, obtain curated content material and talk about illness administration with different group members. We’re very excited to accomplice with Biogen on this chance given their management within the MS house.”
THE LARGER TREND
Happify has been on a partnership tear in latest months. Earlier this month, the digital therapeutic firm announced a collaboration that’s centered on girls’s well being with insurer Anthem, which is quickly to be rebranded to Elevance Well being.
In March, Happify entered into an settlement with healthcare-services and pharmaceutical firm Zuellig Pharma to commercialize two of its prescription digital therapeutics in Asia.
The startup additionally not too long ago launched a digital program for folks with psoriasis in Spain, Italy and the U.Okay. as a part of a partnership with Barcelona-based pharma firm Almirall. Happify additionally closed a $73 million Sequence D funding spherical in March 2021.
Biogen is not new to the digital well being house both. In Might, it entered right into a licensing settlement with prescription digital therapeutics startup MedRhythms to develop and commercialize its MR-004 product, which goals to enhance mobility for folks with a number of sclerosis.
Discussion about this post